17:57 , Jan 19, 2017 |  BC Innovations  |  Translation in Brief

Pockets against pain

Amgen Inc. (NASDAQ:AMGN) is aiming to tackle neuropathic pain by boosting glycine receptor α 3 (GLRA3) activity in the CNS. In a December study, the company presented preclinical data and crystal structures for its GLRA3...
20:49 , Jan 18, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Pain Cell culture and mouse studies identified a positive allosteric modulator (PAM) of GLRA3 that could help treat neuropathic pain. High throughput screening and chemical synthesis to optimize hits yielded a tricyclic sulfonamide-based GLRA3 PAM...
08:00 , Feb 13, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

This week in techniques Approach Summary Licensing status Publication and contact information Disease models Mouse models of epilepsy and anxiety A study in mice suggests neuron type-specific perturbation...
07:00 , Oct 28, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Apnea Glycine receptor a3 (GLRA3); serotonin (5-HT1A) receptor Studies in mice suggest that activation of 5-HT1A receptors...